NYSE:CC - Chemours Stock Price, Price Target & More

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours announced a quarterly dividend on Tuesday, May 1st. Investors of record on Thursday, May 17th will be given a dividend of $0.17 per share on Friday, June 15th. This represents a $0.68 annualized dividend and a dividend yield of 1.50%. The ex-dividend date is Wednesday, May 16th. View Chemours' Dividend History.

Chemours declared that its board has initiated a stock repurchase program on Monday, December 4th 2017, which allows the company to buyback $500,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.

Chemours Co (NYSE:CC) posted its earnings results on Thursday, May, 3rd. The specialty chemicals company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.19. The specialty chemicals company had revenue of $1.73 billion for the quarter, compared to analysts' expectations of $1.65 billion. Chemours had a return on equity of 107.89% and a net margin of 13.79%. Chemours's revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 earnings per share. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Chemours.

11 equities research analysts have issued twelve-month price objectives for Chemours' shares. Their forecasts range from $48.00 to $68.00. On average, they expect Chemours' stock price to reach $59.40 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Ratings for Chemours.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Chemours include Koninklijke DSM (RDSMY), ASAHI KASEI Cor/ADR (AHKSY), FMC (FMC), Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), W. R. Grace & Co (GRA), Olin (OLN), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), PQ Group (PQG), GCP Applied Technologies (GCP), Innospec (IOSP) and KMG Chemicals (KMG).

News articles about CC stock have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Chemours earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news headlines about the specialty chemicals company an impact score of 47.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Chemours' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Selz Capital LLC (0.19%), Retirement Systems of Alabama (0.19%), Scout Investments Inc. (0.18%), Capital One National Association (0.09%), Westpac Banking Corp (0.07%) and Bank of Montreal Can (0.07%). Company insiders that own Chemours stock include Amy Trojanowski, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Paul Kirsch and Richard H Brown. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Bank of Montreal Can, Municipal Employees Retirement System of Michigan, Retirement Systems of Alabama, Fjarde AP Fonden Fourth Swedish National Pension Fund, Capital One National Association, Westpac Banking Corp and State of Alaska Department of Revenue. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including Selz Capital LLC, Clinton Group Inc., Assenagon Asset Management S.A., Exane Derivatives, James Investment Research Inc., Polianta Ltd, Cornerstone Wealth Management LLC and Oakbrook Investments LLC. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $45.23.

Chemours has a market capitalization of $8.15 billion and generates $6.18 billion in revenue each year. The specialty chemicals company earns $746 million in net income (profit) each year or $3.82 on an earnings per share basis. Chemours employs 7,000 workers across the globe.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19899. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]